Survivin expression in canine spontaneous cutaneous and subcutaneous tumors and its prognostic importance

Kavya, N; S, Rao; Ml, Sathyanarayana; Narayanaswamy, HD; Sm, Byregowda; Ranganath, L.R.; Kamaran, A; Km, Purushotham; Tk, Kishore

doi:10.14202/vetworld.2017.1286-1291

Cited by 5 publications

(4 citation statements)

References 32 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prognostic relevance of survivin has been investigated in humans, associated higher survivin concentrations with a poor prognosis and lower survival rates [ 1 8 28 ]. In veterinary medicine, the prognostic relevance of survivin was investigated primarily for osteosarcoma and cutaneous and subcutaneous tissue tumors, showing mixed results depending on the tumor entity [ 17 18 ]. Based on the follow-up information in approximately 16% of the dogs in the present study, there was no correlation between the serum survivin concentration and the outcome of the disease.…”

Section: Discussionmentioning

confidence: 99%

“…Research into biomarkers in veterinary medicine has become a focus and could have the potential for veterinary oncology. Most studies examined the appearance of survivin in tissues, which usually requires invasive investigatory methods [ 17 18 ]. Only a few studies have evaluated the survivin concentrations in the sera of tumor-bearing dogs [ 19 20 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Investigation of serum survivin in dogs suffering from cancer: a multicenter study

Estaller

Kessler²,

Wehrend

et al. 2021

J Vet Sci

View full text Add to dashboard Cite

Background In contrast to human medicine, only a small number of serum tumor markers are established in veterinary medicine even though they are a non-invasive diagnostic tool. Objectives This study examined whether survivin could be suitable as a potential canine serum tumor marker. Methods This study measured the serum survivin concentrations of dogs with mammary tumors (n = 33), squamous cell carcinoma (n = 9), soft-tissue sarcoma (n = 18) and multicentric lymphoma (n = 22), using a commercially available, competitive immunoassay kit (BlueGene). The serum survivin concentrations were compared with those of a healthy control group (n = 20) and a control group of dogs with non-neoplastic diseases (n = 17). Results Dogs with malignant tumors had serum survivin concentrations between 15 and 5,906 pg/mL (median, 72 pg/mL), those in the healthy group ranged from 7 to 99 pg/mL (median, 21 pg/mL) and those in the group of dogs suffering from non-neoplastic diseases from 15 to 93 pg/mL (median, 42 pg/mL). The differences in the survivin concentrations between the healthy dogs and dogs with malignant tumors and between the dogs with non-neoplastic diseases and those with malignant tumors were significant ( p < 0.001 and p = 0.006, respectively). Conclusions The serum survivin concentrations in dogs with malignant tumors, with some exceptions, are higher than in dogs with benign tumors and dogs that do not suffer from a malignancy. Therefore, survivin can provide information on the presence of malignant tumors and be used as a tumor marker in dogs.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Investigation of serum survivin in dogs suffering from cancer: a multicenter study

Estaller

Kessler²,

Wehrend

et al. 2021

J Vet Sci

View full text Add to dashboard Cite

show abstract

“…In an additional study [62], nuclear survivin was also detected in 50% of cystitis tissues whereas cytoplasmic survivin was only detected in 8% of these tissues. In 2017, a study comparing canine tumors of different origins (epithelial, mesenchymal and round-cell tumors) showed that survivin was significantly increased in malignant versus benign tumors (p < 0.05) at the transcriptional level [64]. Finally, in 2020, the survivin inhibitor EZN-3042 was shown to be well-tolerated in a phase I clinical trial of dogs with lymphoma, opening new avenues for the clinical targeting of this protein in veterinary oncology [65].…”

Section: Evasion Of Apoptosis-the Role Of Survivinmentioning

confidence: 99%

Comparative Cancer Cell Signaling in Muscle-Invasive Urothelial Carcinoma of the Bladder in Dogs and Humans

et al. 2021

View full text Add to dashboard Cite

Muscle-invasive urothelial carcinoma (MIUC) is the most common type of bladder malignancy in humans, but also in dogs that represent a naturally occurring model for this disease. Dogs are immunocompetent animals that share risk factors, pathophysiological features, clinical signs and response to chemotherapeutics with human cancer patients. This review summarizes the fundamental pathways for canine MIUC initiation, progression, and metastasis, emerging therapeutic targets and mechanisms of drug resistance, and proposes new opportunities for potential prognostic and diagnostic biomarkers and therapeutics. Identifying similarities and differences between cancer signaling in dogs and humans is of utmost importance for the efficient translation of in vitro research to successful clinical trials for both species.

show abstract

“…Survivin is a bi-functional protein that promotes cell growth by inhibiting apoptosis. It is overexpressed in many cancers including breast [ 11 ], esophagus [ 12 ], lung [ 13 ], lymphoma [ 14 ], and others [ 15 – 17 ]. CXCR4 is a chemokine receptor that is expressed on most hematopoietic cells [ 18 ].…”

Section: Introductionmentioning

confidence: 99%

Analysis of endogenous and exogenous tumor upregulated promoter expression in canine tumors

et al. 2020

View full text Add to dashboard Cite

Gene therapy is a promising treatment option for cancer. However, its utility may be limited due to expression in off-target cells. Cancer-specific promoters such as telomerase reverse transcriptase (TERT), survivin, and chemokine receptor 4 (CXCR4) have enhanced activity in a variety of human and murine cancers, however, little has been published regarding these promoters in dogs. Given the utility of canine cancer models, the activity of these promoters along with adenoviral E2F enhanced E1a promoter (EEE) was evaluated in a variety of canine tumors, both from the endogenous gene and from exogenously administered constructs. Endogenous expression levels were measured for cTERT, cSurvivin, and cCXCR4 and were low for all three, with some non-malignant and some tumor cell lines and tissues expressing the gene. Expression levels from exogenously supplied promoters were measured by both the number of cells expressing the construct and the intensity of expression in individual cells. Exogenously supplied promoters were active in more cells in all tumor lines than in normal cells, with the EEE promoter being most active, followed by cTERT. The intensity of expression varied more with cell type than with specific promoters. Ultimately, no single promoter was identified that would result in reliable expression, regardless of the tumor type. Thus, these findings imply that identification of a pan-cancer promoter may be difficult. In addition, this data raises the concern that endogenous expression analysis may not accurately predict exogenous promoter activity.

show abstract

Survivin expression in canine spontaneous cutaneous and subcutaneous tumors and its prognostic importance

Cited by 5 publications

References 32 publications

Investigation of serum survivin in dogs suffering from cancer: a multicenter study

Investigation of serum survivin in dogs suffering from cancer: a multicenter study

Comparative Cancer Cell Signaling in Muscle-Invasive Urothelial Carcinoma of the Bladder in Dogs and Humans

Analysis of endogenous and exogenous tumor upregulated promoter expression in canine tumors

Contact Info

Product

Resources

About